News Column

Enzymatics to Highlight Targeted Next Generation Sequencing Technology for Cancer Research at AGBT 2014

February 6, 2014



BEVERLY, Mass.--(BUSINESS WIRE)-- Enzymatics, Inc., a leading producer of molecular biology reagents, kits, assays and software, today announced that it is hosting a workshop, “Targeted Next Generation Sequencing for Oncology Research,” during the Advances in Genome Biology & Technology (AGBT) conference on Friday, February 14, from noon to 2:00 p.m. The event will feature presentations by leading scientists, focused on novel sequencing assays in cancer research. The AGBT conference is being held in Marco Island, Florida, February 12-15, 2014.

Cancer research is rapidly unraveling the complex roles of genetic mutations in oncology, leading to targeted approaches where molecular pathology plays a critical role in identifying and monitoring treatment responsive populations as well as in discovering new therapeutic targets. There is a growing need for novel methods like next generation sequencing (NGS) based assays that are rapid, scalable, and capable of detecting a wide range of mutation types.

Enzymatics’ workshop will focus on the application of NGS assays based on Anchored Multiplex PCR (AMP™) technology, a new approach to target enrichment for sensitive detection of gene rearrangements, single nucleotide variants, insertions, deletions, copy number variants or changes in RNA abundance. Conference attendees can register at www.enzymatics.com/agbt-registration.

Presentations and featured speakers are:

  • Anchored Multiplex PCR for Targeted Next Generation Sequencing

    Long Le, M.D., Ph.D.,Assistant in Pathology, Massachusetts General Hospital
  • RNA Fusion Assay Development for the Broad Clinical Research Sequencing Platform

    Niall Lennon, Ph.D.,Director of Technology Development, Clinical Applications and Automation Engineering, Genomics Platform, Broad Institute of MIT and Harvard
  • Development and Integration of Clinical Oncology NGS Testing

    Robert Daber, Ph.D.,Technical Director of Clinical Genomics, University of Pennsylvania School of Medicine
  • Sequencing Library Research at the Sanger Institute

    Michael Quail, Ph.D.,Sequencing R&D Team Leader, Wellcome Trust Sanger Institute

    In its 15th year, AGBT brings together scientific leaders from various disciplines that are being advanced by DNA sequencing and genome exploration. The conference is recognized throughout the sequencing community as the cornerstone for the discussion of genomics research, providing an excellent forum for exchanging innovations in sequencing technologies and applications. Follow developments at AGBT 2014 on Twitter with #ABGT14.

    About Enzymatics

    Enzymatics is a leading producer of sample preparation reagents, assays, kits and software for life science research and applied science customers worldwide. We are experts in the fields of DNA sequencing and PCR, and our business units include:

    - Reagents

    - Supply Chain Solutions

    - Applied Science

    Our passion for quality, responsiveness and flexibility is catalyzing the genomic healthcare revolution. www.enzymatics.com




    Enzymatics

    Glen Gagnon, +1 978 927 7027

    ggagnon@enzymatics.com

    or

    For media

    MacDougall Biomedical Communications

    Charles Liles, +1-781-235-3060

    cliles@macbiocom.com

    Source: Enzymatics, Inc.


  • For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



    Source: Business Wire


    Story Tools